Effects of Acarbose Versus Glibenclamide on Glycemic Excursion and Oxidative Stress in Type 2 Diabetic Patients Inadequately Controlled by Metformin: A 24-Week, Randomized, Open-Label, Parallel-Group Comparison

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages 1932-1942

  Wang, Jun Sing ^a   Lin, Shi Dou ^b   Lee, Wen Jane ^a   Su, Shih Li ^b   Lee, I Te ^a,c,d   Tu, Shih Te ^b   Tseng, Yao Hsien ^a   Lin, Shih Yi ^a,c   Sheu, Wayne Huey Herng ^a,c,d,e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

cell function; Continuous glucose monitoring; Glycemic excursion; Oxidative stress; Type 2 diabetes

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACARBOSE; ADIPONECTIN; C REACTIVE PROTEIN; CREATININE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ABDOMINAL DISTENSION; ADD ON THERAPY; ADULT; ARTHRALGIA; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; DIABETES CONTROL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLYCEMIC EXCURSION; HUMAN; HYPOGLYCEMIA; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ACARBOSE; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DINOPROST; DRUG THERAPY, COMBINATION; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; LIPOPROTEINS, LDL; MALE; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; OUTPATIENTS; OXIDATIVE STRESS; REGRESSION ANALYSIS; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 83455220076     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.014     Document Type: Article

References (35)

1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
2. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
3. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003, 26:881-885.
4. Wang J.S., Tu S.T., Lee I.T., et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev 2011, 27:79-84.
5. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004, 47:385-394. DECODA Study Group.
6. Cavalot F., Petrelli A., Traversa M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006, 91:813-819.
7. Ceriello A., Esposito K., Piconi L., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57:1349-1354.
8. Monnier L., Mas E., Ginet C., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
9. Service F.J., Molnar G.D., Rosevear J.W., et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970, 19:644-655.
10. Monnier L., Colette C., Owens D.R. Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab Res Rev 2009, 25:393-402.
11. Hanefeld M., Cagatay M., Petrowitsch T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25:10-16.
12. Rösen P., Osmers A. Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose. Horm Metab Res 2006, 38:575-586.
13. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
14. Cheng S.F., Hsu H.H., Lee H.S., et al. Rational pharmacotherapy in the diabetic hypertension: analysis-prescribing patterns in a general hospital in Taiwan. J Clin Pharm Ther 2004, 29:547-558.
15. Schwedhelm E., Bartling A., Lenzen H., et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004, 109:843-848.
16. Mastrototaro J. The MiniMed Continuous Glucose Monitoring System (CGMS). J Pediatr Endocrinol Metab 1999, 12:751-758.
17. Chen H.S., Wu T.E., Jap T.S., et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008, 31:1927-1932.
18. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
19. Koubaa N., Nakbi A., Smaoui M., et al. Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem 2007, 40:1007-1014.
20. Fujinami A., Ohta K., Obayashi H., et al. Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: relationship to glucose metabolism and biomarkers of insulin resistance. Clin Biochem 2008, 41:812-817.
21. Blüher M., Brennan A.M., Kelesidis T., et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007, 30:280-285.
22. Lee I.T., Sheu W.H., Lin S.Y., et al. Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. J Diabetes Complications 2002, 16:382-385.
23. Keaney J.F., Larson M.G., Vasan R.S., et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003, 23:434-439.
24. Monnier L., Colette C., Mas E., et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010, 53:562-571.
25. Altman D.G. Practical Statistics for Medical Research 1991, Chapman and Hall, London, UK.
26. Phung O.J., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
27. Fischer S., Patzak A., Rietzsch H., et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab 2003, 5:38-44.
28. Kohnert K.D., Augstein P., Zander E., et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009, 32:1058-1062.
29. Zhang L., Qiao Q., Tuomilehto J., et al. Blood lipid levels in relation to glucose status in seven populations of Asian origin without a prior history of diabetes: the DECODA study. Diabetes Metab Res Rev 2009, 25:549-557.
30. Mughal M.A., Memon M.Y., Zardari M.K., et al. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes. J Pak Med Assoc 2000, 50:152-156.
31. Ochiai H., Ooka H., Shida C., et al. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J 2008, 55:549-556.
32. Ozeki N., Hara K., Yatsuka C., et al. Serum high-molecular weight adiponectin decreases abruptly after an oral glucose load in subjects with normal glucose tolerance or impaired fasting glucose, but not those with impaired glucose tolerance or diabetes mellitus. Metabolism 2009, 58:1470-1476.
33. Sun J., Xu Y., Deng H., et al. Intermittent high glucose exacerbates the aberrant production of adiponectin and resistin through mitochondrial superoxide overproduction in adipocytes. J Mol Endocrinol 2010, 44:179-185.
34. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
35. Helmersson J., Basu S. F2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids 1999, 61:203-205.